Meeting report: Risk assesment of Tamiflu use under pandemic conditions

Environmental Health Perspectives

Volumn 116, Issue 11, 2008, Pages 1563-1567

  Singer, Andrew C ^a   Howard, Bruce M ^b   Johnson, Andrew C ^a   Knowles, Chris J ^b   Jackman, Simon ^b   Accinelli, Cesare ^c   Caracciolo, Anna Barra ^d   Bernard, Ian ^b   Bird, Stephen ^e   Boucard, Tatiana ^f   Boxall, Alistair ^g   Brian, Jayne V ^h   Cartmell, Elise ⁱ   Chubb, Chris ^f   Churchley, John ^j   Costigan, Sandra ^e   Crane, Mark ^k   Dempsey, Michael J ^l   Dorrington, Bob ^m   Ellor, Brian ⁿ   Fick, Jerker ^o   Holmes, John ^b   Hutchinson, Tom ^p   Karcher, Franz ^q   Kelleher, Samuel L ^l   Marsden, Peter ^r   Noone, Gerald ^s   Nunn, Miles A ^a   Oxford, John ^t   Rachwal, Tony ^e   Roberts, Noel ^u   Roberts, Mike ^v   Saccà, Maria Ludovica ^c   Sanders, Matthew ^w   Straub, Jürg Oliver ^u   Terry, Adrian ^x   Thomas, Dean ^v   Toovey, Stephen ^u   Townsend, Rodney ^y   Voulvoulis, Nikolaos ^a   Watts, Chris ^k   more..

^a CENTRE FOR ECOLOGY AND HYDROLOGY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d CNR   (Italy)

^e South West Water ^*

^f ENVIRONMENT AGENCY   (United Kingdom)

^g UNIVERSITY OF YORK   (United Kingdom)

^h BRUNEL UNIVERSITY   (United Kingdom)

ⁱ CRANFIELD UNIVERSITY   (United Kingdom)

^j SEVERN TRENT WATER LTD   (United Kingdom)

^k WCA ENVIRONMENT LTD   (United Kingdom)

^l MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

^m Northumbrian Water Ltd   (United Kingdom)

ⁿ UNITED UTILITIES   (United Kingdom)

^o UMEÅ UNIVERSITY   (Sweden)

^p ASTRAZENECA   (United Kingdom)

^q EUROPEAN COMMISSION   (Belgium)

^r DRINKING WATER INSPECTORATE   (United Kingdom)

^s Worshipful Company of Water Conservators   (United Kingdom)

^t QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^u F Hoffmann La Roche Ltd   (Switzerland)

^v CENTRE FOR ENVIRONMENT   (United Kingdom)

^w Cambridge Environmental Assessments   (United Kingdom)

^x ROYAL SOCIETY OF CHEMISTRY   (United Kingdom)

^y IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Antiviral; Drug; Ecotoxicology; Influenza; Pandemic; Pharmaceutical; Pollution; Sewage treatment plant; Tamiflu

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; RIVER WATER; SIALIDASE INHIBITOR;

AQUATIC ENVIRONMENT; CATCHMENT; CONFERENCE PAPER; DRUG SAFETY; DRUG USE; ECOTOXICITY; ECOTOXICOLOGY; ENVIRONMENTAL EXPOSURE; FRESHWATER SPECIES; HEALTH HAZARD; HUMAN; INFLUENZA; JAPAN; PANDEMIC; PRIORITY JOURNAL; RISK ASSESSMENT; SEWAGE EFFLUENT; SEWAGE TREATMENT PLANT; VIRUS RESISTANCE; WATER CONTAMINATION;

HUMANS; INFLUENZA, HUMAN; OSELTAMIVIR; RISK ASSESSMENT;

EID: 58849121407     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.11310     Document Type: Conference Paper

References (39)

1. Accinelli C, Caracciolo AB, Grenni P. 2007. Degradation of the antiviral drug oseltamivir carboxylate in surface water samples. Int J Environ Anal Chem 87(8):579-587.
2. Anonymous. 2007. Levels of resistance to oseltamivir remain low in community isolates of influenza virus in Japan. Inpharma 1:19.
3. Aoki FY, Boivin G, Roberts N. 2007. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 12(4 PtB):603-616.
4. Chutinimitkul S, Suwannakarn K, Chieochansin T, Mai LQ, Damrongwatanapokin S, Chaisingh A, et al. 2007. H5N1 Oseltamivir-resistance detection by real-time PCR using two high sensitivity labeled TaqMan probes. J Virol Methods 139(1): 44-49.
5. Department of Health and Human Services. 2006. Pandemic Planning Update: A Report from Secretary Michael O. Leavitt, March 13, 2006. Available: http://www.hhs.gov/pan.u20060313.pdf [accessed 30 September 2008].
6. ECETOC. 2007. Intelligent Testing Strategies in Ecotoxicology: Mode of Action Approach for Specifically Acting Chemicals. Technical Report 102. Brussels:European Centre for Ecotoxicology and Toxicology of Chemicals. Available: http://staging.idweaver.com/ECETOC/Documents/TR%20102.pdf [accessed 30 September 2008].
7. EISS (European Influenza Surveillance Scheme). 2007. Pandemic Plans on the Internet. Available: http://www.eiss.org/html/ pandemic_plans.html [accessed 30 September 2008].
8. EMEA (European Medicines Agency). 2005. Tamiflu: European Public Assessment Report. Available: http://www.emea.europa.eu/humandocs/Humans/ EPAR/tamiflu/tamiflu.htm [accessed 15 May 2008].
9. EMEA (European Medicines Agency). 2006. Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use. EMEA/CHMP/SWP/4447/ 00. Available: http://www.emea.europa.eu/pdfs/human/swp/444700en.pdf [accessed 1 October 2008].
10. Environment Agency. 2003. Targeted Monitoring Programme for Pharmaceuticals in the Aquatic Environment. Bristol, UK:Environment Agency.
11. Environment Agency. 2008. Prioritisation of Pharmaceuticals of Potential Environmental Concern. R&D Technical Report. Bristol, UK:Environment Agency.
12. European Commission. 2003. Technical Guidance Document on Risk Assessment. Commission Directive 93/67/EEC, Commission Regulation (EC) No 1488/94, Directive 98/8/EC Available: http://ecb.jrc.it/tgd/ [accessed 17 April 2008].
13. F. Hoffmann-La Roche. 2007. Tamiflu: Pharmacological properties. Available: http://emc.medicines.org.uk/emc/assets/c/html/ DisplayDoc.asp?DocumentID=10701#PHARMACOLOGICAL_PROPS [accessed 30 September 2008].
14. Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, Burke DS. 2006. Strategies for mitigating an influenza pandemic. Nature 442(7101): 448-452.
15. Ferraris O, Kessler N, Lina B. 2005. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res 68(1):43-48.
16. Fick J. 2007. Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: implications for development of resistance by influenza A virus. PLoS ONE 2(10):e986; doi:10.1371/journal.pone.0000986 [Online 3 October 2007].
17. Hayden FG. 2006. Antivirals for influenza: historical perspectives and lessons learned. Antiviral Res 71(2-3):372-378.
18. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. 2007. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res 73(3):228-231.
19. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. 2003. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 163(14):1667-1672.
20. Keller VDJ, Whelan MJ, Rees HG. 2006. A global assessment of chemical effluent dilution capacities from a macro-scale hydrological model. In: Climate Variability and Change - Hydrological Impacts. IAHS Publication no. 308. Wallingford, UK:IAHS Press, Institute of Hydrology, 586-590.
21. Lipsitch M, Cohen T, Murray M, Levin BR. 2007. Antiviral Resistance and the Control of Pandemic Influenza. PLoS Med 4(1):e15; doi:10.1371/ journal.pmed.0040015 [Online 23 January 2007].
22. Moscona A, McKimm-Breschkin J. 2007. News about influenza B drug resistance that cannot be ignored [Editorial]. JAMA 297(13):1492-1493.
23. Mounier-Jack S, Jas R, Coker R. 2007. Progress and shortcomings in European national strategic plans for pandemic influenza. Bull WHO 85(12):923-929.
24. Nicholson KG, Aoki FY, Osterhaus ADME, Trottier S, Carewicz O, Mercier CH, et al. 2000. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 355:1845-1850.
25. OECD. 1984. OECD Guidelines for Testing of Chemicals: Alga, Growth Inhibition Test. OECD TG 201. In: Annex I: OECD Test Guidelines for Studies Included in the SIDS. Available: http://www.oecd.org/dataoecd/17/ 22/1948257.pdf [accessed 7 October 2008].
26. OECD. 1992. OECD Guidelines for Testing of Chemicals: Fish, Early Life Stage Toxicity Test. OECD TG 210' In: Annex I: OECD Test Guidelines for Studies Included in the SIDS. Available: http://www.oecd.org/dataoecd/17/ 62/1948269.pdf [accessed 7 October 2008].
27. OECD. 1998. OECD Guidelines for Testing of Chemicals: Daphnia magna Reproduction Test. OECD TG 211. In: Annex I: OECD Test Guidelines for Studies Included in the SIDS. Available: http://www.oecd.org/dataoecd/17/63/1948277.pdf [accessed 7 October 2008].
28. Roberts NA. 2001. Treatment of influenza with neuraminidase inhibitors: virological implications. Phil Trans R Soc Lond B 356(1416):1895-1897.
29. Scientific Pandemic Influenza Advisory Committee. 2008 Statement Providing Scientific Advice on Stockpiling Neuraminidase Inhibitors. Available: http://www.advisorybodies.doh.gov.uk/spi/ spi2008-01neuraminidasestockpiling.pdf [accessed 16 July 2008].
30. Singer AC, Nunn MA, Gould EA, Johnson AC. 2007. Potential risks associated with the widespread use of Tamiflu. Environ Health Perspect 115:102-106.
31. Smee DF, Sidwell RW. 2002. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. Expert Opin Investig Drugs 11(6):859-869.
32. Soong G, Muir A, Gomez MI, Waks J, Reddy B, Planet P, et al. 2006. Bacterial neuraminidase facilitates mucosal infection by participating in biofilm production. J Clin Invest 116(8):2297-2305.
33. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. 2000. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 283(8):1016-1024.
34. Ward P, Small I, Smith J, Suter P, Dutkowski R. 2005. Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 55(suppl 1):i5-i21.
35. Whitley RJ, Hayden RG, Reisinger KS, Young N, Dutkowski R, Ipe D, et al. 2000. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20(2):127-133.
36. WHO (World Health Organization). 2006a. WHO Rapid Advice Guidelines on pharmacological management of humans infected with avian influenza A (H5N1) virus (May 2006). Available: http://www.who.int/csr/disease/ avian_influenza/guidelines/pharmamanagement/en/index.html [accessed 1 October 2008].
37. WHO (World Health Organization). 2006b. Pandemic Influenza Draft Protocol for Rapid Response and Containment (Updated Draft 17 March 2006). Available: http://www.who.int/csr/disease/avian_influenza/ guidelines/pandemic.uprotocol_17.03a.pdf [accessed 30 September 2008].
38. WHO. 2007. Clinical Management of Human Infection with Avian Influenza A (H5N1) Virus (updated advice 15 August 2007). Available: http://www.who.int/csr/disease/avian_influenza/guidelines/ ClinicalManagement07.pdf [accessed 1 October 2008].
39. Yen H-L, Herlocher LM, Hoffmann E, Matrosovich MN, Monto AS, Webster RG, et al. 2005. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 49(10):4075-4084.